DeepMed Research

Fluciclovine

Generic Name: Fluciclovine

Drug Type: Small Molecule

Chemical Formula: C_₅H_₈FNO_₂

CAS Number: 222727-43-7

Unique Ingredient Identifier: YKG0YF688X

Background: Fluciclovine is under investigation in clinical trial NCT03036943 (Fluciclovine (18F) Imaging of Breast Cancer).

Clinical Trials

18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

Phase 1

Recruiting

Conditions: Brain Metastases, Adult
Brain Cancer
Brain Metastases

Interventions: Drug: 18F fluciclovine

First Posted Date: 2023-09-21

Last Posted Date: 2025-05-18

Lead Sponsor: Baptist Health South Florida

Target Recruit Count: 46

Registration Number: NCT06048094

Locations: 🇺🇸
Miami Cancer Institute, Miami, Florida, United States

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

Phase 4

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Fluciclovine PET/CT

First Posted Date: 2023-02-10

Last Posted Date: 2025-01-10

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 50

Registration Number: NCT05722925

Locations: 🇺🇸
Oregon Health & Science University, Portland, Oregon, United States

Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR

Early Phase 1

Withdrawn

Conditions: Brain Metastases
Glioblastoma
Gliomas
Cancer

Interventions: Drug: F18 Fluciclovine
Other: Standard of Care

First Posted Date: 2021-09-23

Last Posted Date: 2023-09-01

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT05054400

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Radiotherapy Planning Using Fluciclovine PET in Patients With Newly Diagnosed Glioblastoma

Phase 2

Recruiting

Conditions: Newly Diagnosed Glioblastoma

Interventions: Drug: Fluciclovine PET guided Radiotherapy

First Posted Date: 2021-04-09

Last Posted Date: 2023-01-13

Lead Sponsor: St. Joseph's Hospital and Medical Center, Phoenix

Target Recruit Count: 100

Registration Number: NCT04840069

Locations: 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States

Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

Phase 1

Recruiting

Conditions: Brain Cancer
Brain Metastases
Brain Metastases, Adult

Interventions: Drug: 18F fluciclovine

First Posted Date: 2020-12-30

Last Posted Date: 2025-01-17

Lead Sponsor: Baptist Health South Florida

Target Recruit Count: 20

Registration Number: NCT04689048

Locations: 🇺🇸
Miami Cancer Institute, Miami, Florida, United States

Study to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)

Phase 2

Completed

Conditions: Brain Metastases

Interventions: Drug: 18F fluciclovine

First Posted Date: 2020-06-01

Last Posted Date: 2023-08-01

Lead Sponsor: Blue Earth Diagnostics

Target Recruit Count: 23

Registration Number: NCT04410367

Locations: 🇺🇸
University Hospital Cleveland, Cleveland, Ohio, United States
🇺🇸
University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸
Miami Cancer Institute, Miami, Florida, United States

and more 6 locations

Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

Phase 3

Completed

Conditions: Brain Metastases

Interventions: Drug: 18F fluciclovine

First Posted Date: 2020-06-01

Last Posted Date: 2023-07-12

Lead Sponsor: Blue Earth Diagnostics

Target Recruit Count: 151

Registration Number: NCT04410133

Locations: 🇺🇸
West Virgina University Cancer Institute, Morgantown, West Virginia, United States
🇺🇸
Medical College of Georgia, Augusta University, Augusta, Georgia, United States
🇺🇸
John Wayne Cancer Institute at Providence St. John's Health Center, Santa Monica, California, United States

and more 16 locations

Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer.

Phase 4

Terminated

Conditions: Cervical Cancer
Uterine Cancer

Interventions: Drug: 18F fluciclovine
Device: 18F fluciclovine PET

First Posted Date: 2018-02-06

Last Posted Date: 2020-10-28

Lead Sponsor: Nghi Nguyen

Target Recruit Count: 1

Registration Number: NCT03423082

Locations: 🇺🇸
UPMC Presbyterian - MR Research Center, Pittsburgh, Pennsylvania, United States

Pretreatment Staging of High-Risk Prostate Cancer With 18F-Fluciclovine PET/MRI

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Diagnostic Test: [18F] Fluciclovine PET/MRI
Drug: [18F] fluciclovine

First Posted Date: 2017-08-29

Last Posted Date: 2020-03-09

Lead Sponsor: University of Alabama at Birmingham

Target Recruit Count: 18

Registration Number: NCT03264456

Locations: 🇺🇸
University of Alabama at Birmingham Medical Center, Birmingham, Alabama, United States

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy